| Nov 18 |
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases
|
| Nov 15 |
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
|
| Nov 13 |
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November
|
| Nov 13 |
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024
|
| Nov 13 |
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024...
|
| Nov 12 |
Life Sciences Investor Forum Agenda Announced for November 14th
|
| Nov 7 |
NeuroBo Pharmaceuticals GAAP EPS of -$0.55 beats by $0.18
|
| Nov 7 |
NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 4 |
NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
|
| Oct 1 |
NRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25…
|
